Skip to content
10-Q

Quarterly Report

Adamas Pharmaceuticals, Inc.

0001328143-20-000050

← back to feed
Filed
Nov 5, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Oct 30, 2020 28.52M sh
Long Term Debt Q3 2020 · Sep 30, 2020 $126.57M
Long Term Debt Q3 2020 · Dec 31, 2019 $125.67M
Short Term Debt Q3 2020 · Sep 30, 2020 $3.23M
Short Term Debt Q3 2020 · Dec 31, 2019 $2.04M
Short Term Investments Q3 2020 · Sep 30, 2020 $41.67M
Short Term Investments Q3 2020 · Dec 31, 2019 $66.83M
Cash And Equivalents Q3 2020 · Sep 30, 2020 $50.8M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $65.77M
Current Liabilities Q3 2020 · Sep 30, 2020 $31.49M
Current Liabilities Q3 2020 · Dec 31, 2019 $26.95M
Total Liabilities Q3 2020 · Sep 30, 2020 $167.42M
Total Liabilities Q3 2020 · Dec 31, 2019 $163.05M
Current Assets Q3 2020 · Sep 30, 2020 $123.94M
Current Assets Q3 2020 · Dec 31, 2019 $150.32M
Total Assets Q3 2020 · Sep 30, 2020 $132.8M
Total Assets Q3 2020 · Dec 31, 2019 $162.16M
Capex Q3 2020 · Sep 30, 2019 $18K
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$62.47M
Stockholders Equity Q3 2020 · Sep 30, 2019 $19.76M
Stockholders Equity Q3 2020 · Jun 30, 2019 $42.7M
Stockholders Equity Q3 2020 · Mar 31, 2019 $63.92M
Stockholders Equity Q3 2020 · Dec 31, 2018 $89.89M
Sga Expense Q3 2020 · Sep 30, 2019 $31.18M
Sga Expense Q3 2020 · Sep 30, 2019 $84.08M
Rd Expense Q3 2020 · Sep 30, 2019 $6.04M
Rd Expense Q3 2020 · Sep 30, 2019 $24.85M
Net Income Q3 2020 · Sep 30, 2019 −$27.58M
Net Income Q3 2020 · Sep 30, 2019 −$82.11M
Net Income Q3 2020 · Jun 30, 2019 −$24.87M
Net Income Q3 2020 · Mar 31, 2019 −$29.66M
Operating Income Q3 2020 · Sep 30, 2019 −$24.22M
Operating Income Q3 2020 · Sep 30, 2019 −$72.68M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $929K
Cost Of Revenue Q3 2020 · Sep 30, 2019 $2.03M
Revenue Q3 2020 · Sep 30, 2019 $13.93M
Revenue Q3 2020 · Sep 30, 2019 $38.29M